MedTrace Logo

Gleevec and Gemzar in Patients With Epithelial Ovarian Cancer

NCT00928642 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2014-10-21

Study results available
· View outcomes & findings →

Summary

This study will evaluate the efficacy and tolerability of the combination of Gleevec and Gemzar in patients with ovarian cancer, who have progressed after receiving at least one prior chemotherapy treatment. Gleevec is an oral chemotherapy drug used is this study and Gemzar is an IV chemotherapy drug used. Participation in the treatment portion of the study will continue as long as the patient's tumors shrink or remain stable and as long as the patient is able to tolerate the study drug. The follow-up portion of the study will last for 5 years.

Conditions

Interventions

DRUG

imatinib mesylate by mouth

imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.

DRUG

Gemcitabine Intravenous

Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Henry M. Jackson Foundation for the Advancement of Military Medicine

    lead OTHER

Principal Investigators

  • David McCune, MD, MPH · Madigan Army Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-06-30
Primary Completion
2010-11-30
Completion
2010-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00928642 on ClinicalTrials.gov